Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/edm2.247 http://scihub22266oqcxt.onion/10.1002/edm2.247 34277971!8279612!34277971     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Endocrinol+Diabetes+Metab 2021 ; 4 (3): e00247 Nephropedia Template TP {{tp|p=34277971|t=2021. Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program |pdf=|usr=}}{{34277971}} gab.com Text Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program JO: Endocrinol Diabetes Metab http://www.kidney.de/pget.php?&tw=1&pmid=34277971 #FOAvip BACKGROUND: Patients with type 2 diabetes (T2D) are predisposed to derangements in serum Magnesium (Mg), which may have implications for cardiometabolic events and outcomes. In clinical trials, participants with T2D randomized to sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown mild to moderate increases in serum Mg from baseline levels. This post hoc analysis assesses the relation between serum Mg with cardiovascular outcomes in 10,140 participants of the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program. METHODS: We evaluated the association of baseline serum Mg with the primary composite end point of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke, and tested whether this association is modified by baseline serum Mg. Using mediation analysis, we determined whether change in serum Mg post-randomization mediates the beneficial effect of canagliflozin on cardiovascular outcomes. RESULTS: Mean serum Mg levels at baseline were 0.77 +/- 0.09 mmol/L in both canagliflozin group and placebo groups. The canagliflozin group experienced an average increase in serum Mg by 0.07 mmol/L (95% CI, 0.065-0.072 mmol/L; p < .001) for the duration of the trial. We found no association between baseline serum Mg levels and the primary composite end point, and no evidence of effect modification by baseline Mg levels. Change in serum Mg post-randomization was not a mediator of the effects of canagliflozin on cardiovascular outcomes. CONCLUSIONS: In participants of the CANVAS Program, baseline and post-randomization serum Mg levels are not associated with cardiovascular outcomes. Twit Text FOAVip Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program ????Endocrinol Diabetes Metab http://www.kidney.de/pget.php?&tw=1&pmid=34277971 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34277971 #FOAvip English Wikipedia <ref>{{Cite pmid|34277971}}</ref> Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program #MMPMID34277971 Wang KM; Li J; Bhalla V; Jardine MJ; Neal B; de Zeeuw D; Fulcher G; Perkovic V; Mahaffey KW; Chang TI Endocrinol Diabetes Metab 2021[Jul]; 4 (3): e00247 PMID34277971show ga BACKGROUND: Patients with type 2 diabetes (T2D) are predisposed to derangements in serum Magnesium (Mg), which may have implications for cardiometabolic events and outcomes. In clinical trials, participants with T2D randomized to sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown mild to moderate increases in serum Mg from baseline levels. This post hoc analysis assesses the relation between serum Mg with cardiovascular outcomes in 10,140 participants of the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program. METHODS: We evaluated the association of baseline serum Mg with the primary composite end point of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke, and tested whether this association is modified by baseline serum Mg. Using mediation analysis, we determined whether change in serum Mg post-randomization mediates the beneficial effect of canagliflozin on cardiovascular outcomes. RESULTS: Mean serum Mg levels at baseline were 0.77 +/- 0.09 mmol/L in both canagliflozin group and placebo groups. The canagliflozin group experienced an average increase in serum Mg by 0.07 mmol/L (95% CI, 0.065-0.072 mmol/L; p < .001) for the duration of the trial. We found no association between baseline serum Mg levels and the primary composite end point, and no evidence of effect modification by baseline Mg levels. Change in serum Mg post-randomization was not a mediator of the effects of canagliflozin on cardiovascular outcomes. CONCLUSIONS: In participants of the CANVAS Program, baseline and post-randomization serum Mg levels are not associated with cardiovascular outcomes. |*Cardiovascular System[MESH] |*Diabetes Mellitus, Type 2[MESH] |*Sodium-Glucose Transporter 2 Inhibitors/pharmacology[MESH] |Canagliflozin/pharmacology/therapeutic use[MESH] |Humans[MESH] |Magnesium/pharmacology/therapeutic use[MESH]Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis fr(epmc).pdf DeepDyve Pubget Overpricing